ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study

(2:35)

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

(43)

CASPIAN Trial: Durvalumab and Chemotherapy in ES-SCLC

(6:37)

Adjuvant Pembrolizumab, Durvalumab, and More Considerations From UC Trials Presented at ESMO 2024

(3:47)

Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

(4:41)

Trying a New Hairstyle - My Daughter Misses \

(23:44)

Eden’s journey with IMFINZI® (durvalumab)

(4:4)

I Made a Mistake - Sudden Upsurge in Grief - Superbowl Sunday

(18:)

MOA of IMFINZI in 1L mNSCLC

(14:33)

Durvalumab - Imfinzi - All You Need to Know in 2 Minutes.

(2:49)

July 25, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

(5:19:55)

NIAGARA Study Insights: Durvalumab \u0026 Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas

(15:30)

How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science Illustrated

(2:44)

No benefit for adjuvant durvalumab in completely resected NSCLC

(6:35)

Mickey and his caregiver, Carla, talk about IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl)

(9:10)

Dr. Feldman on the Future of Durvalumab and Tremilimumab in NSCLC

(1:42)

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in ...

(8:50)

RAD-IO: assessing the feasibility of durvalumab with CRT in bladder cancer

(2:1econd)

Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder Cancer

(2:36)

ARCADIA: evaluating durvalumab and cabozantinib in variant histology tumors

(1:34)

Evaluating real-world efficacy of durvalumab and tremelimumab in HCC

(1:2)

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

(2:10)

DUTRENEO: durvalumab and tremelimumab vs chemo

(2:12)

Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer

(4:16)

Durvalumab following chemoradiotherapy improves survival in patients with limited-stage small-ce...

(4:33)

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

(2:43)

Durvalumab and oleclumab in patients with relapsed ovarian cancer

(3:3)

Durvalumab and Tremelimumab Before Surgery in Breast Cancer Patients | Oncotarget

(1:59)

Neo-CheckRay: chemotherapy and SBRT with durvalumab and oleclumab in ER+/HER2- breast cancer

(54)